Artículo
NK cells and solid tumors therapeutic potential and persisting obstacles
Autor/es | Tong, Le
Jiménez Cortegana, Carlos Tay, Apple H.M. Wickström, Stina Galluzzi, Lorenzo Lundqvist, Andreas |
Departamento | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología |
Fecha de publicación | 2022-11-01 |
Fecha de depósito | 2023-05-04 |
Publicado en |
|
Premios | Premio Mensual Publicación Científica Destacada de la US. Facultad de Medicina Premio Anual Publicación Científica Destacada de la US. Facultad de Medicina |
Resumen | Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging responses in patients ... Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging responses in patients with leukemia, the therapeutic effects of NK cell infusion in patients with solid tumors are limited. Preclinical and clinical data suggest that the efficacy of NK cell infusion against solid malignancies is hampered by several factors including inadequate tumor infiltration and persistence/activation in the tumor microenvironment (TME). A number of metabolic features of the TME including hypoxia as well as elevated levels of adenosine, reactive oxygen species, and prostaglandins negatively affect NK cell activity. Moreover, cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells actively suppress NK cell-dependent anticancer immunity. Here, we review the metabolic and cellular barriers that inhibit NK cells in solid neoplasms as we discuss potential strategies to circumvent such obstacles towards superior therapeutic activity. |
Agencias financiadoras | 2019 Laura Ziskin Prize in Translational Research Cancer Research Foundations of Radiumhemmet Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US) donations from Promontory (New York, US) Functional Genomics Initiative (New York, US) Leukemia and Lymphoma Society (LLS) Luke Heller TECPR2 Foundation (Boston, US) Lytix Biopharma (Oslo, Norway) NIH/NCI Noxopharm (Chatswood, Australia) Onxeo (Paris, France) Ricerchiamo (Brescia, Italy) romontory (New York, US) Sotio a.s. (Prague, Czech Republic) Stand Up to Cancer (SU2C) Swedish Cancer Society Swedish Childhood Cancer Foundation US DoD BCRP |
Identificador del proyecto | ZP-6177
211253 CA274291 21 1524 Pj BC180476P1 BC210945 W81XWH2120034 |
Cita | Tong, L., Jiménez Cortegana, C., Tay, A.H.M., Wickström, S., Galluzzi, L. y Lundqvist, A. (2022). NK cells and solid tumors therapeutic potential and persisting obstacles. Molecular Cancer, 21 (1), 206. https://doi.org/10.1186/s12943-022-01672-z. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
NK cells and solid tumors ... | 1.996Mb | [PDF] | Ver/ | |